Skip to Content

Oragenics Inc OGEN

Morningstar Rating
$1.02 −0.10 (8.93%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OGEN is trading within a range we consider fairly valued.
Price
$1.01
Fair Value
$5.47
Uncertainty
Extreme
1-Star Price
$62.72
5-Star Price
$2.25
Economic Moat
Fsth
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.12
Day Range
$1.001.14
52-Week Range
$0.977.74
Bid/Ask
$1.01 / $1.07
Market Cap
$5.69 Mil
Volume/Avg
228,046 / 132,813

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
5

Valuation

Metric
OGEN
Price/Earnings (Normalized)
Price/Book Value
4.43
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
OGEN
Quick Ratio
2.28
Current Ratio
2.69
Interest Coverage
−594.10
Quick Ratio
OGEN

Profitability

Metric
OGEN
Return on Assets (Normalized)
−260.25%
Return on Equity (Normalized)
−441.05%
Return on Invested Capital (Normalized)
−308.44%
Return on Assets
OGEN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
YqsddbgzMmbr$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
LsxkfzjqxWyrwzx$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
VsrpnlxmdFzbwyr$117.6 Bil
Moderna Inc
MRNA
BgtxkwhjLhzg$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
NjjdbjnMcqblr$29.9 Bil
argenx SE ADR
ARGX
WygfncqqMhqgs$27.7 Bil
BioNTech SE ADR
BNTX
QdgqwgxkNsdq$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
GdcrwzbmHqvng$15.8 Bil
United Therapeutics Corp
UTHR
RqvngdxwgVqc$14.6 Bil
Incyte Corp
INCY
WrmzsyqNtwjycr$12.9 Bil

Sponsor Center